ReviewFrontiers in pharmacology2026
Exocytosed ATP as a therapeutic target for inflammatory and metabolic diseases.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular adenosine triphosphate (eATP) is a key intercellular signaling molecule in purinergic transmission and contributes to pain, inflammation, and tissue dysfunction in a wide range of diseases. Although eATP is released through membrane damage, conductive pathways, and vesicular exocytosis, the biological and pharmacological significance of ATP released by exocytosis has remained insufficiently defined. Vesicular nucleotide transporter (VNUT), encoded by SLC17A9, which loads ATP into secretory vesicles, is essential for ATP exocytosis and has enabled direct investigation of the roles of exocytosed ATP in physiology and disease. Accumulating evidence indicates that VNUT-dependent ATP exocytosis contributes to inflammatory signaling, sensory transmission, metabolic dysregulation, and cancer-related processes, while its inhibition shows therapeutic potential in experimental models of pathological states. This review summarizes recent advances in the molecular basis, regulation, pharmacological manipulation, and disease relevance of VNUT-mediated ATP exocytosis. We also discuss the therapeutic potential of targeting exocytosed ATP for pain, chronic inflammation, and metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.